The identification of effective therapies for multiple sclerosis remains a significant priority and challenge for those in research, clinical practice and industry who are trying to find new methods to both manage and prevent the disease. Recent years have seen success in the development of disease-modifying therapies but what are the next steps?
In this feature we will be looking at the advancements that have been made in the treatment landscape for various forms of multiple sclerosis, including what challenges remain in their development. We will also be exploring what emerging therapies may be on the horizon and how these developments may improve patient outcomes.
In this podcast, we spoke with Gavin Giovannoni (Barts and the London School of Medicine and Dentistry, London, UK) about the biggest challenges surrounding the development of therapies for multiple sclerosis, including what advancements have been made in disease-modifying therapies.
This infographic explores MAVENCLAD (cladribine tablets) as a treatment option for multiple sclerosis in terms of its potential benefits, clinical evidence, mechanism of action and safety profile.